Market News

Citigroup analyst Keith Horowitz maintains Goldman Sachs Group (NYSE:GS) with a Neutral and raises the price target from $1100 to $1200.

Vista Energy (NYSE:VIST) reported quarterly earnings of $2.90 per share which missed the analyst consensus estimate of $54.36 by 94.67 percent. This i...

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smalle...

https://www.sec.gov/ix?doc=/Archives/edgar/data/1627475/000162747526000042/upwork-20260714.htm

Wise Group (NASDAQ:WSE) reported quarterly sales of $714.000 million which beat the analyst consensus estimate of $517.176 million by 38.06 percent. ...

MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.

Citigroup analyst Fatima Boolani maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Buy and raises the price target from $195 to $250.

Small-cap stocks are staging their most dominant run against the S&P 500 in over two decades, and three ETFs are competing for the best seat at the ta...

Visa Inc. (NYSE: V) has launched a new enterprise platform that brings stablecoin issuance, wallets and payment mov...

Abbott Laboratories (NYSE:ABT) shares rose nearly 11% on Thursday after the healthcare company reported second quarter 2026 results that topped Wall S...

Yesterday the PHLX Semiconductor Index ended the session down 2%, but the Nasdaq closed in the green, up 0.6%. Today the chip index is down roughly 4....

Amazon stock and Google are buys because of massive AI distribution while Meta has to prove its strategy, Wedbush says.

Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises the price target from $82 to $93.

Cathie Wood has been scooping up shares of this nuclear company in recent days.

Humana (HUM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Investors don't just have to look at up-and-coming fintech stocks to gain adequate exposure.

Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $75 to $76.

By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W...

South Plains Financial, Inc. (NASDAQ:SPFI) ("South Plains"), the parent company of City Bank, today announced that its Board of Directors has ...